The global radioimmunoassay market was valued at US$ 433.9 Million in 2022 and is expected to reach US$ 690.8 Million by 2033. The clinical use segment with a market share more than 82.0% has topped the global market within the purpose category and is expected to grow at a CAGR of close to 3.8% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 433.9 Million |
| Market Value 2023 | US$ 451.0 Million |
| Market Value 2033 | US$ 690.8 Million |
| CAGR 2023 to 2033 | 4.4% |
| Market Share of Top 5 Countries | 57.7% |
| Key Market Players | PerkinElmer Inc., Berthold Technologies GmbH & Co.KG, LKB Instruments, Montreal Biotech, DIAsource, Abbexa, IBL International GmbH, Creative Biolabs, MP BIOMEDICALS, ALPCO, Padyab Teb Co., Merck KGaA, NovoLytiX GmbH, Beckman Coulter, Inc., DiaSorin S.p.A., DRG INSTRUMENTS GMBH, and EUROIMMUN Medizinische Labordiagnostika AG. |
The foundation of radioimmunoassay (RIA) is the formation of antigen-antibody complexes as a result of the competition between labelled and unlabelled antigens for certain antibody sites. Radioimmunoassay is an extremely sensitive method for measuring antigen quantities without the use of a conventional bioassay. RIA is used to estimate the antigenicity of compounds, either naturally or through chemical modification. Hormones, tumour indicators (peptides, proteins, steroids, etc.), vitamins, medicines, and other substances all can be estimated by using this technique.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The historical market for radioimmunoassay was around 1.1% of the overall global immunoassay market US$ 40.2 Billion in 2022. Demographic factor as population size, age, distribution and disease prevalence can influence the RIA market. The aging population is more prone to diseases and needs diagnosis. Technological advancement in kit development can help to provide improved, automated and rapid diagnostic methods. These factors significantly shape the demand, adoption, and growth of the market on a global scale. It is essential for businesses operating in this market to closely monitor and understand these factors to make informed decisions and strategies.
Another major health-related issue is diabetes.
Somatostatin levels are measured using a radioimmunoassay (RIA) but require a longer duration for the development of results. Scientists have undertaken a task to transform the kit into a straightforward handheld gadget that can be mass-produced in a short period. These major applications of radioimmunoassay technology will boost demand for it globally.
The availability and quality of healthcare infrastructure, including hospitals, clinics, and diagnostic centers, can impact the adoption of radioimmunoassay. Regions with well-developed healthcare systems are more likely to embrace and integrate advanced medical technologies.
An opportunity exists for the radioimmunoassay industry due to the growth in cancer, chronic illnesses, infectious diseases, therapeutic drug monitoring, and drug addiction throughout the world as well as its use in the diagnosis of autoimmune diseases, cardiology, and endocrinology. This technology can aid in the early detection, monitoring, and management of these conditions, leading to improved patient outcomes.
Collaborations and partnerships between healthcare providers, research institutions, and technology companies can foster innovation and accelerate the adoption of radioimmunoassay. Joint efforts in research, development, and commercialization can lead to the expansion of market reach and the development of new applications.
This initiative has helped local RIA kits manufacturer to develop and promote their products within the country. This provides an opportunity for emerging and local manufacturers to expand in the market.
Principal Consultant
The market faces competition from alternative diagnostic technologies such as stable free radicals, fluorochromes, chemiluminescence precursors, enzyme inhibitors, and methods. These are easy to handle, can give qualitative and quantitative information and easy to discard post experiment.
This competition can limit market penetration and slow down the growth of radioimmunoassay, particularly in regions where other technologies are more established. It is largely restricted to immunoassays, the need for expensive reagents and equipment and the requirements for licensing and containment. Another important problem is disposal of radioactive waste management, special training and license required and expensive instrumentation.
The USA occupies 29.8% share in global RIA market in the year 2022. The USA has a significant burden of chronic diseases such as obesity, diabetes and cardiovascular diseases. Radioimmunoassay is used in the assessing and managing of these conditions, making it relevant and in demand within the USA healthcare system. The USA has a competitive medical device market, with various manufacturers and suppliers offering radioimmunoassay kit and related products. The demand for radioimmunoassay in the USA market is driven by the need for accurate and invasive diagnostic tools.
The Germany accounts for US$ 38.0 Million in the global market in 2022. Germany boasts a skilled and well-trained healthcare workforce, including physicians, researchers, and technicians. These professionals are knowledgeable in the use and interpretation of radioimmunoassay data, enabling widespread adoption and application of the technology in clinical practice and research. Prominent immunodiagnostic kit developing industries are located in Germany giving it an upper hand in market.
China held a dominant share of the East Asia market and contributed around US$ 35.8 Million in 2022. The country's swiftly expanding middle class has boosted expenditure on healthcare and disposable money. The need for better-quality healthcare goods, like radioimmunoassay, has increased as a result of demographic shifts. The rising middle class's increased disposable income has helped the Chinese economy expand. The Chinese population is second largest in world making it a huge market for disease diagnostics, RIA being able to identify high level of sensitivity is prominently used for diagnosis many china a large market for radioimmunoassay.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Kits & reagents accounted for US$ 262.9 Million, representing a sizable 60.2% global market share in 2022. The kits and reagents are inexpensive, simple to use, and readily available. They offer great specificity and selectivity, delivering thorough information on biomolecule diagnosis. The compounds are simple to produce and ship as kits, making them readily available. Reagent and kit manufacture takes less time; therefore, they are always ready when needed.
The infectious disease segment accounted for the predominant share in the global market, with a revenue share of 33.5% in 2022. Mutations in bacteria and viruses have increased the prevalence of infectious illnesses in recent years. Bacterial strains that are multi-drug resistant have rapidly developed, and viruses' pathogenicity has increased significantly in parallel. Infectious illness cases have increased as a result, necessitating an immediate and precise diagnosis. Since RIA makes this possible, the segment is the most profitable segment for radioimmunoassay market.
The hospitals have a considerable presence in the global market accounting for 27.4% market share in 2022 and expected to grow at a CAGR of 5.4%. When in pain, individuals with and without chronic or infectious disorders visit hospitals. Because nurses and doctors are well-trained and knowledgeable to handle and comprehend these procedures, hospitals are the most beneficial end user in the market.
The clinical use segment contributes US$ 356.6 Million globally in 2022. A significant number of RIA kits are the result of research and development, but their primary function is the detection and identification of a particular molecular target. A vast number of disorders are associated with variations in biomolecule levels. Based on the results of the initial screening, patients are then directed onto RIA, which provides thorough health information. The variety of radioimmunoassay are utilised for clinical purposes since once standardised, an assay does not require further study.
Serum accounted for US$ 179.6 Million market value in 2022. The sizeable amount of RIAs used to diagnose diseases are carried out on patient serum. Since the serum circulates throughout the body, it contains the most freely floating biomolecules that are present in a person. Serum is easily available, has high amount of antigen, and can be used for multiple test other than RIA, hence it is preferred over saliva, urine, plasma and cell culture sample.
The market for radioimmunoassay is fragmented in nature with numerous prominent firms competing in the market. Collaborations and agreements between healthcare providers, research institutions, and tech companies can spur innovation and speed up the spread of radioimmunoassay. Investment in research and development with commercialization of technologically improved products can lead to market expansion. Among the well-known players in this field are:
Similarly, recent developments related to the companies in the radioimmunoassay market have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | US$ Million for Value & Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, France, Spain, Russia, Italy, BENELUX, UK, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam, China, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye, South Africa and Northern Africa. |
| Key Market Segments Covered | Product, Application, Purpose, Sample Type, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage |
|
| Pricing | Available upon Request |
The market is estimated to secure a valuation of US$ 451.0 million in 2023.
The global market size is expected to reach US$ 690.8 million by 2033.
The growth potential of the market is 4.4% through 2033.
The market share of top five countries is 57.7%.
There are two types of RIA, including coated-tube RIA and double-antibody RIA.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Product Adoption Analysis
4.2. Product USPs/Features Analysis
4.3. Regulatory Landscape, By Country
4.4. Disease Epidemiology, By Key Indication
4.5. Porter’s Analysis
4.6. PESTLE Analysis
4.7. Value Chain Analysis
4.8. Unmet Needs Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Life Science Market Outlook
5.1.3. Global Immunoassay Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Cases of Chronic Illness
5.2.2. Increase in Research and Development
5.2.3. Government Initiative for Early Diagnosis
5.2.4. Growth of Clinical Diagnostics
5.2.5. Technological Advancements
5.2.6. Cost of Product
5.2.7. Adoption Rate
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2012 to 2022
6.2. Current and Future Market Volume (Units) Analysis and Forecast Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis By Product
7.2. Global Average Pricing Analysis Benchmark
7.3. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
8.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) and Volume (Units) By Product, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Kits and Reagents
9.3.1.1. Kits
9.3.1.2. Antibodies
9.3.2. Instruments
9.3.3. Consumables
9.3.4. Services
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Application, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033
10.3.1. Oncology
10.3.2. Cardiology
10.3.3. Endocrinology
10.3.4. Infectious Disease
10.3.5. Autoimmune Disease
10.3.6. Therapeutic Drug Monitoring
10.3.7. Drug of Abuse
10.3.8. Others
10.4. Market Attractiveness Analysis By Application
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Purpose
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Purpose, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Purpose, 2023 to 2033
11.3.1. Research Use Only
11.3.2. Clinical Use
11.4. Market Attractiveness Analysis By Purpose
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample Type
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Sample Type, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sample Type, 2023 to 2033
12.3.1. Serum
12.3.2. Plasma
12.3.3. Urine
12.3.4. Saliva
12.3.5. Cell Culture Sample
12.4. Market Attractiveness Analysis By Sample Type
13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
13.3.1. Hospital
13.3.2. Specialty Clinics
13.3.3. Academic and Research Institute
13.3.4. Diagnostics Laboratories
13.3.5. Reference Laboratories
13.3.6. Cancer Research Institutes
13.3.7. Veterinary Hospitals
13.4. Market Attractiveness Analysis By End User
14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis Forecast By Region, 2023 to 2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Application
15.3.4. By Purpose
15.3.5. By Sample Type
15.3.6. By End User
15.4. Market Attractiveness Analysis By Region
15.4.1. By Country
15.4.2. By Product
15.4.3. By Application
15.4.4. By Purpose
15.4.5. By Sample Type
15.4.6. By End User
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. USA Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Application
15.8.1.2.3. By Purpose
15.8.1.2.4. By Sample Type
15.8.1.2.5. By End User
15.8.2. Canada Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Application
15.8.2.2.3. By Purpose
15.8.2.2.4. By Sample Type
15.8.2.2.5. By End User
16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Application
16.3.4. By Purpose
16.3.5. By Sample Type
16.3.6. By End User
16.4. Market Attractiveness Analysis By Region
16.4.1. By Country
16.4.2. By Product
16.4.3. By Application
16.4.4. By Purpose
16.4.5. By Sample Type
16.4.6. By End User
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Brazil Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Application
16.8.1.2.3. By Purpose
16.8.1.2.4. By Sample Type
16.8.1.2.5. By End User
16.8.2. Mexico Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Application
16.8.2.2.3. By Purpose
16.8.2.2.4. By Sample Type
16.8.2.2.5. By End User
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Application
16.8.3.2.3. By Purpose
16.8.3.2.4. By Sample
16.8.3.2.5. Type By End User
17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. France
17.3.1.3. Spain
17.3.1.4. Russia
17.3.1.5. Italy
17.3.1.6. BENELUX
17.3.1.7. UK
17.3.1.8. Rest of Europe
17.3.2. By Product
17.3.3. By Application
17.3.4. By Purpose
17.3.5. By Sample Type
17.3.6. By End User
17.4. Market Attractiveness Analysis By Region
17.4.1. By Country
17.4.2. By Product
17.4.3. By Application
17.4.4. By Purpose
17.4.5. By Sample Type
17.4.6. By End User
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Germany Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Application
17.8.1.2.3. By Purpose
17.8.1.2.4. By Sample Type
17.8.1.2.5. By End User
17.8.2. France Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Application
17.8.2.2.3. By Purpose
17.8.2.2.4. By Sample Type
17.8.2.2.5. By End User
17.8.3. Spain Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Application
17.8.3.2.3. By Purpose
17.8.3.2.4. By Sample
17.8.3.2.5. Type By End User
17.8.4. Russia Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Application
17.8.4.2.3. By Purpose
17.8.4.2.4. By Sample
17.8.4.2.5. Type By End User
17.8.5. Italy Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Product
17.8.5.2.2. By Application
17.8.5.2.3. By Purpose
17.8.5.2.4. By Sample Type
17.8.5.2.5. By End User
17.8.6. BENELUX Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Product
17.8.6.2.2. By Application
17.8.6.2.3. By Purpose
17.8.6.2.4. By Sample Type
17.8.6.2.5. By End User
17.8.7. UK Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Product
17.8.7.2.2. By Application
17.8.7.2.3. By Purpose
17.8.7.2.4. By Sample Type
17.8.7.2.5. By End User
18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Thailand
18.3.1.4. Philippines
18.3.1.5. Malaysia
18.3.1.6. Vietnam
18.3.1.7. Rest of South Asia
18.3.2. By Product
18.3.3. By Application
18.3.4. By Purpose
18.3.5. By Sample Type
18.3.6. By End User
18.4. Market Attractiveness Analysis By Region
18.4.1. By Country
18.4.2. By Product
18.4.3. By Application
18.4.4. By Purpose
18.4.5. By Sample Type
18.4.6. By End User
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. India Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Application
18.8.1.2.3. By Purpose
18.8.1.2.4. By Sample Type
18.8.1.2.5. By End User
18.8.2. Indonesia Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Application
18.8.2.2.3. By Purpose
18.8.2.2.4. By Sample Type
18.8.2.2.5. By End User
18.8.3. Thailand Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product
18.8.3.2.2. By Application
18.8.3.2.3. By Purpose
18.8.3.2.4. By Sample Type
18.8.3.2.5. By End User
18.8.4. Philippines Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Product
18.8.4.2.2. By Application
18.8.4.2.3. By Purpose
18.8.4.2.4. By Sample Type
18.8.4.2.5. By End User
18.8.5. Malaysia Market Analysis
18.8.5.1. Introduction
18.8.5.2. Market Analysis and Forecast by Market Taxonomy
18.8.5.2.1. By Product
18.8.5.2.2. By Application
18.8.5.2.3. By Purpose
18.8.5.2.4. By Sample Type
18.8.5.2.5. By End User
18.8.6. Vietnam Market Analysis
18.8.6.1. Introduction
18.8.6.2. Market Analysis and Forecast by Market Taxonomy
18.8.6.2.1. By Product
18.8.6.2.2. By Application
18.8.6.2.3. By Purpose
18.8.6.2.4. By Sample Type
18.8.6.2.5. By End User
19. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. By Product
19.3.3. By Application
19.3.4. By Purpose
19.3.5. By Sample Type
19.3.6. By End User
19.4. Market Attractiveness Analysis By Region
19.4.1. By Country
19.4.2. By Product
19.4.3. By Application
19.4.4. By Purpose
19.4.5. By Sample Type
19.4.6. By End User
19.5. Market trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. China Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Application
19.8.1.2.3. By Purpose
19.8.1.2.4. By Sample Type
19.8.1.2.5. By End User
19.8.2. Japan Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Application
19.8.2.2.3. By Purpose
19.8.2.2.4. By Sample Type
19.8.2.2.5. By End User
19.8.3. South Korea Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Application
19.8.3.2.3. By Purpose
19.8.3.2.4. By Sample Type
19.8.3.2.5. By End User
20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
20.1. Introduction / Key Findings
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
20.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Application
20.3.4. By Purpose
20.3.5. By Sample Type
20.3.6. By End User
20.4. Market Attractiveness Analysis By Region
20.4.1. By Country
20.4.2. By Product
20.4.3. By Application
20.4.4. By Purpose
20.4.5. By Sample Type
20.4.6. By End User
20.5. Market trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Product
20.8.1.2.2. By Application
20.8.1.2.3. By Purpose
20.8.1.2.4. By Sample Type
20.8.1.2.5. By End User
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Product
20.8.2.2.2. By Application
20.8.2.2.3. By Purpose
20.8.2.2.4. By Sample Type
20.8.2.2.5. By End User
21. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
21.1. Introduction / Key Findings
21.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022
21.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. South Africa
21.3.1.4. Northern Africa
21.3.1.5. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Application
21.3.4. By Purpose
21.3.5. By Sample Type
21.3.6. By End User
21.4. Market Attractiveness Analysis By Region
21.4.1. By Country
21.4.2. By Product
21.4.3. By Application
21.4.4. By Purpose
21.4.5. By Sample Type
21.4.6. By End User
21.5. Market trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Product
21.8.1.2.2. By Application
21.8.1.2.3. By Purpose
21.8.1.2.4. By Sample Type
21.8.1.2.5. By End User
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Product
21.8.2.2.2. By Application
21.8.2.2.3. By Purpose
21.8.2.2.4. By Sample Type
21.8.2.2.5. By End User
21.8.3. South Africa Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Product
21.8.3.2.2. By Application
21.8.3.2.3. By Purpose
21.8.3.2.4. By Sample Type
21.8.3.2.5. By End User
21.8.4. Northern Africa Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Product
21.8.4.2.2. By Application
21.8.4.2.3. By Purpose
21.8.4.2.4. By Sample Type
21.8.4.2.5. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players (%)
22.3. Market Presence Analysis
22.3.1. Regional Footprint of Players
22.3.2. Product Footprint of Players
22.3.3. Channel Footprint of Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Key Development Analysis
23.3. Branding and Promotional Strategies, By Key Players
23.4. Competition Deep Dive
23.4.1. PerkinElmer Inc.
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Key Financials
23.4.1.4. Sales Footprint
23.4.1.5. SWOT Analysis
23.4.1.6. Strategy Overview
23.4.1.6.1. Marketing Strategies
23.4.1.6.2. Channel Strategies
23.4.1.6.3. Product Strategies
23.4.2. Berthold Technologies GmbH & Co.KG
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Key Financials
23.4.2.4. Sales Footprint
23.4.2.5. SWOT Analysis
23.4.2.6. Strategy Overview
23.4.2.6.1. Marketing Strategies
23.4.2.6.2. Channel Strategies
23.4.2.6.3. Product Strategies
23.4.3. LKB Instruments
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Key Financials
23.4.3.4. Sales Footprint
23.4.3.5. SWOT Analysis
23.4.3.6. Strategy Overview
23.4.3.6.1. Marketing Strategies
23.4.3.6.2. Channel Strategies
23.4.3.6.3. Product Strategies
23.4.4. Montreal Biotech
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Key Financials
23.4.4.4. Sales Footprint
23.4.4.5. SWOT Analysis
23.4.4.6. Strategy Overview
23.4.4.6.1. Marketing Strategies
23.4.4.6.2. Channel Strategies
23.4.4.6.3. Product Strategies
23.4.5. DIAsource
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Key Financials
23.4.5.4. Sales Footprint
23.4.5.5. SWOT Analysis
23.4.5.6. Strategy Overview
23.4.5.6.1. Marketing Strategies
23.4.5.6.2. Channel Strategies
23.4.5.6.3. Product Strategies
23.4.6. Abbexa
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Key Financials
23.4.6.4. Sales Footprint
23.4.6.5. SWOT Analysis
23.4.6.6. Strategy Overview
23.4.6.6.1. Marketing Strategies
23.4.6.6.2. Channel Strategies
23.4.6.6.3. Product Strategies
23.4.7. IBL International GmbH
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Key Financials
23.4.7.4. Sales Footprint
23.4.7.5. SWOT Analysis
23.4.7.6. Strategy Overview
23.4.7.6.1. Marketing Strategies
23.4.7.6.2. Channel Strategies
23.4.7.6.3. Product Strategies
23.4.8. Creative Biolabs
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Key Financials
23.4.8.4. Sales Footprint
23.4.8.5. SWOT Analysis
23.4.8.6. Strategy Overview
23.4.8.6.1. Marketing Strategies
23.4.8.6.2. Channel Strategies
23.4.8.6.3. Product Strategies
23.4.9. MP Biomedicals
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Key Financials
23.4.9.4. Sales Footprint
23.4.9.5. SWOT Analysis
23.4.9.6. Strategy Overview
23.4.9.6.1. Marketing Strategies
23.4.9.6.2. Channel Strategies
23.4.9.6.3. Product Strategies
23.4.10. ALPCO
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Key Financials
23.4.10.4. Sales Footprint
23.4.10.5. SWOT Analysis
23.4.10.6. Strategy Overview
23.4.10.6.1. Marketing Strategies
23.4.10.6.2. Channel Strategies
23.4.10.6.3. Product Strategies
23.4.11. Padyab Teb Co.
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Key Financials
23.4.11.4. Sales Footprint
23.4.11.5. SWOT Analysis
23.4.11.6. Strategy Overview
23.4.11.6.1. Marketing Strategies
23.4.11.6.2. Channel Strategies
23.4.11.6.3. Product Strategies
23.4.12. Merck KGaA
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Key Financials
23.4.12.4. Sales Footprint
23.4.12.5. SWOT Analysis
23.4.12.6. Strategy Overview
23.4.12.6.1. Marketing Strategies
23.4.12.6.2. Channel Strategies
23.4.12.6.3. Product Strategies
23.4.13. NovoLytiX GmbH
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Key Financials
23.4.13.4. Sales Footprint
23.4.13.5. SWOT Analysis
23.4.13.6. Strategy Overview
23.4.13.6.1. Marketing Strategies
23.4.13.6.2. Channel Strategies
23.4.13.6.3. Product Strategies
23.4.14. Beckman Coulter, Inc.
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Key Financials
23.4.14.4. Sales Footprint
23.4.14.5. SWOT Analysis
23.4.14.6. Strategy Overview
23.4.14.6.1. Marketing Strategies
23.4.14.6.2. Channel Strategies
23.4.14.6.3. Product Strategies
23.4.15. DiaSorin S.p.A.
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Key Financials
23.4.15.4. Sales Footprint
23.4.15.5. SWOT Analysis
23.4.15.6. Strategy Overview
23.4.15.6.1. Marketing Strategies
23.4.15.6.2. Channel Strategies
23.4.15.6.3. Product Strategies
23.4.16. DRG INSTRUMENTS GMBH
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Key Financials
23.4.16.4. Sales Footprint
23.4.16.5. SWOT Analysis
23.4.16.6. Strategy Overview
23.4.16.6.1. Marketing Strategies
23.4.16.6.2. Channel Strategies
23.4.16.6.3. Product Strategies
23.4.17. EUROIMMUN Medizinische Labordiagnostika AG
23.4.17.1. Overview
23.4.17.2. Product Portfolio
23.4.17.3. Key Financials
23.4.17.4. Sales Footprint
23.4.17.5. SWOT Analysis
23.4.17.6. Strategy Overview
23.4.17.6.1. Marketing Strategies
23.4.17.6.2. Channel Strategies
23.4.17.6.3. Product Strategies
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Radioimmunoassay Market
